Saffron Walden, UK (17 April 2013) – BioFocus announced today that it has extended its collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease. Based on the success of the project to date, BioFocus will continue the optimization of agents for disease specific biomarkers.
“We have worked with The Michael J. Fox Foundation since 2011 to identify and optimize a-synuclein imaging agents, and are delighted that the progress supports an extension to this collaboration,” said Dr Chris Newton, Managing Director, BioFocus. “The program will utilize BioFocus’ leading biology and chemistry platforms, and will capitalize on the company’s highly experienced teams and state-of-the-art technologies.”
Contacts
BioFocus:
Chris Newton
Tel: +44 1799 533 500
Email: chris.newton@glpg.com
Media enquiries:
Katie Odgaard
Zyme Communications
Tel: +44 7787 502 947
Email: katie.odgaard@zymecommunications.com
About The Michael J. Fox Foundation for Parkinson’s Research
As the world’s largest private funder of Parkinson’s research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $325 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson’s research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson’s disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson’s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.
For more information, visit us on Facebook, Twitter, Web and LinkedIn.
About BioFocus
BioFocus provides integrated drug discovery that delivers pre-clinical drug candidates in all therapeutic areas with strong capabilities in neurodegenerative diseases, inflammatory diseases and rare and neglected diseases. BioFocus has advanced and comprehensive drug discovery capabilities that are applied to client projects to deliver targets, hits, leads and pre-clinical candidates. The company employs over 150 exceptionally qualified and industry experienced scientists at its research centers in the UK and the Netherlands. Since its foundation in 1997, BioFocus has produced high quality data for its clients, assured by ISO9001 qualification, validated by regular independent inspection of all BioFocus research centers. More information can be found at www.biofocus.com.
BioFocus® is a trademark of Galapagos NV and/or its affiliates © Copyright 2013 Galapagos NV.
